
    
      This study is an open-label, Phase 1b study evaluating TRK-950 in combination with 1) FOLFIRI
      or 2) Gemcitabine / Cisplatin or 3) Gemcitabine / Carboplatin or 4) Ramucirumab/Paclitaxel or
      5) PD1 inhibitors (Nivolumab or Pembrolizumab) or 6) Imiquimod Cream for subcutaneous lesions
      7) Bevacizumab or 8) Nivolumab / Ipilimumab in Patients with Selected Advanced Solid Tumors.
      The objectives of this study are to determine the safety, tolerability, MTD, recommended
      Phase 2 dose (RP2D), PK, and preliminary anti-tumor activity of TRK-950 when used in
      combination with other treatment regimens.
    
  